儿童免疫规划间接效应背景下65岁继续接种肺炎球菌结合疫苗的成本效果
该研究采用概率模型随访2019年65岁人群,评估在儿童PCV13规划间接效应背景下,65岁继续推荐PCV13联合PPSV23相比仅推荐PPSV23的增量成本效果。基础情形下每获得一个QALY成本为561,682美元;结论认为儿童PCV13规划的间接效应使继续推荐PCV13的成本 per QALY大幅增加。
要点
- 基础情形下65岁继续推荐PCV13联合PPSV23,每获得一个QALY成本为561,682美元。
- 按既往关于PCV13对3型疾病效果的假设,继续推荐的成本为207,607美元/QALY。
核心结论
- 儿童PCV13规划的间接效应使65岁继续推荐PCV13的每QALY成本在仅数年内大幅增加。
研究设计与样本
- 采用概率模型,随访2019年65岁人群队列,使用健康成人和慢性病成人的接种覆盖率与疾病发病率估计,并纳入儿童PCV13规划对成人疾病发病率的持续间接效应。
主要发现
- 基础情形下,65岁继续推荐PCV13每获得一个QALY成本为561,682美元。
- 在既往关于PCV13对3型疾病效果的假设下,继续推荐的成本为207,607美元/QALY。
- 上述估计高于既往在预测间接效应背景下对该推荐成本效果的估计,原因在于新数据表明PCV13对3型(剩余PCV13型疾病的主要病因)影响有限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The findings and conclusions in this report are those of the authors and do not necessarily represent the official positon of the Centers for Disease Control and Prevention. BACKGROUND: Continued indirect effects provided by the childhood pneumococcal conjugate vaccine (13-valent pneumococcal conjugate vaccine [PCV13]) program in the United States have decreased disease in the adult population, reducing the potential direct effects of vaccinating older adults. OBJECTIVE: We examined the incremental cost-effectiveness of continuing to recommend PCV13 in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) at age 65 compared to a strategy that only included a recommendation for PPSV23 at age 65. METHODS: We used a probabilistic model following a cohort of 65 year olds in 2019. We used vaccination coverage and disease incidence estimates for healthy adults and adults with chronic medical conditions. We incorporated continued indirect effects from the childhood PCV13 program on adult disease incidence. RESULTS: In the base case scenario, continuing to recommend PCV13 at age 65 cost $561,682 per quality-adjusted life year (QALY) gained. In a scenario where PPSV23 provided modest protection against non-invasive pneumococcal pneumonia, costs increased to $2.3 million per QALY. These estimates are larger than our prior estimates for cost-effectiveness of this recommendation in the context of predicted indirect effects due to new data indicating PCV13 provided limited impact on serotype 3, the major cause of the remaining PCV13-type disease. Under our prior assumptions about PCV13 effectiveness against serotype 3 disease, the cost of continuing the recommendation is $207,607 per QALY. CONCLUSION: Indirect effects from the childhood PCV13 program have dramatically increased the cost per QALY of continuing to recommend PCV13 at age 65 after only a few years.
引用
- Stoecker C, Kobayashi M, Matanock A, et al. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program. Vaccine. 2019. PMID: 31889609. doi:10.1016/j.vaccine.2019.12.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。